High and low dose initial thyroxine therapy for congenital hypothyroidism

Area of Science:

• Pediatric Endocrinology
• Neonatal Metabolism
• Thyroid Hormone Replacement

Background:

• Congenital primary hypothyroidism requires lifelong thyroxine (T4) replacement therapy.
• Optimizing initial T4 dosage is crucial for achieving euthyroidism in infants.
• Factors influencing early T4 levels post-initiation require further elucidation.

Purpose of the Study:

• To identify key factors affecting thyroxine (T4) levels one month after initiating replacement therapy in congenital primary hypothyroidism.
• To compare T4 levels in infants receiving high versus low initial T4 doses.
• To investigate the relationship between pretreatment T4, thyroid anatomy, and treatment response.

Main Methods:

• Retrospective analysis of 41 infants with congenital hypothyroidism.
• Review of initial T4 dose (high vs. low), pretreatment T4 levels, and T4 levels at one month post-therapy.
• Thyroid scintiscan performed to assess thyroid anatomy (agenesis vs. ectopia).

Main Results:

• One-month T4 levels significantly correlated with pretreatment T4 levels (r=0.48) and T4 dose (r=0.46).
• Suboptimal T4 levels (< 130 nmol/L) were more frequent in infants with thyroid agenesis (7/11) than ectopia (7/28, P<0.03).
• Infants with suboptimal T4 levels had lower pretreatment T4 than those with optimal levels (21 vs. 48 nmol/L, P<0.02).

Conclusions:

• Infants with congenital hypothyroidism and minimal residual thyroid function (agenesis) require higher initial T4 doses.
• Thyroid anatomy influences the T4 dose needed to achieve therapeutic levels.
• Pretreatment T4 levels and thyroid agenesis are critical factors in early T4 replacement therapy.